Leslie S. Kean, MD, PhD, of Dana-Farber/Boston Children's Cancer and Blood Disorders Center explains the potential impact of abatacept, which is now FDA-approved to prevent acute graft-versus-host disease (GvHD) in patients 2 years of age or older receiving a hematopoietic stem cell transplant from a matched or single-HLA-mismatched unrelated donor.
